Research programme: antithrombotics - Tobira Therapeutics

Drug Profile

Research programme: antithrombotics - Tobira Therapeutics

Alternative Names: RB-571/RB-515; REG3

Latest Information Update: 14 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Archemix Corporation; Regado Biosciences
  • Developer Tobira Therapeutics
  • Class Antithrombins; Nucleotide aptamers; Oligonucleotides
  • Mechanism of Action Glycoprotein inhibitors; Platelet membrane glycoprotein VI inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cardiovascular disorders; Diabetic angiopathies

Most Recent Events

  • 01 Nov 2016 Tobira Therapeutics has been acquired by Allergan
  • 05 May 2015 Regado Biosciences has merged with Tobira Therapeutics and renamed as Tobira Therapeutics
  • 14 Jan 2014 REG3 is still in preclinical development in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top